-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
India Imposes 162.5% Duty on Bulk Scotch Imports Amid UK Trade Pact Dispute
-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled
KELOWNA, BC / ACCESS Newswire / November 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that final dosing has been completed on schedule with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo's® ("Novo") commercially available Wegovy® tablets, over a 5-week duration (the "Study").
Final visits were completed this week by all Study participants within all Study arms. With dosing complete and final blood samples taken, the Study work will now shift to laboratory sample analyses, quality control and review of all data, and then reporting.
No information from the Study will be provided to any third parties until all data has been reviewed and quality controlled. Lexaria will provide further information once that has been achieved.
About the Study
The Study is investigating three separate arms to assess safety & tolerability as well as PK properties that will compare SNAC-inclusive, DHT-sema compositions formulated in both tablet and capsule formats to commercially available Wegovy® tablets. The Study is being conducted under fasted pre-dose conditions similar to the advised administration criteria of Novo's oral semaglutide products. The 5-week dosing duration was selected in order to allow for achievement of steady state concentration levels, meaning that the semaglutide blood quantities in each arm will be expected to reach an equilibrium level that balances drug input with natural bodily elimination.
The Study is exploring several new DehydraTECH™ enhancements not previously evaluated, which include but are not limited to the following two main improvements:
(1) First, an oral tablet DHT-sema composition will be used by Lexaria for the first time, as opposed to only the capsule compositions administered in all our previous DehydraTECH™ GLP-1 studies. Novo's Rybelsus® and Wegovy® oral semaglutide medications use specially formulated tablets designed to temporarily adhere to the stomach lining and disintegrate and dissolve releasing agents in a focal manner that aids in optimizing absorption of semaglutide into the human body. For the first time ever, Lexaria has attempted to mimic and integrate certain physical properties of the Rybelsus® and Wegovy® SNAC-inclusive tablet delivery modality into its DHT-sema tablets to follow established industry standards and thereby increase the likelihood of subsequent commercial pharmaceutical relationships.
(2) Second, both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, which will be the first time these formulations will be evaluated over a multi-dose, multi-week time period in humans. The five-week dosing duration of the Study is expected to be long enough to reach so-called steady-state, which is when drug concentrations in the body reach a constant concentration. As noted above, Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2), conducted in 2024 and 2025 which incorporated SNAC (but did not use tablets), were limited by single-dose study designs and therefore of much shorter duration.
The Study is fully funded from existing corporate resources.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 70 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the satisfaction of customary closing conditions, the intended use of proceeds from the offering, the anticipated closing of the offering, the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
N.Mitchell--AT